Prevest Denpro Ltd
Incorporated in 2000, Prevest DenPro Limited is into development and manufacturing of dental materials used for diagnosis, prevention and treatment of dental conditions. Company is heavily export-oriented.
- Market Cap ₹ 457 Cr.
- Current Price ₹ 381
- High / Low ₹ 622 / 318
- Stock P/E 21.4
- Book Value ₹ 105
- Dividend Yield 0.26 %
- ROCE 24.7 %
- ROE 18.5 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 19 | 23 | 28 | 38 | 50 | 56 | 63 | 72 | |
| 15 | 17 | 19 | 23 | 30 | 36 | 41 | 46 | |
| Operating Profit | 4 | 5 | 9 | 15 | 20 | 20 | 22 | 26 |
| OPM % | 20% | 23% | 32% | 40% | 40% | 36% | 35% | 36% |
| 0 | 2 | 1 | 2 | 2 | 3 | 4 | 5 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | 4 | 6 | 9 | 16 | 21 | 21 | 24 | 29 |
| Tax % | 20% | 20% | 23% | 28% | 25% | 25% | 25% | 25% |
| 3 | 5 | 7 | 12 | 16 | 16 | 18 | 21 | |
| EPS in Rs | 1,049.12 | 1,757.89 | 252.98 | 9.64 | 13.09 | 13.43 | 15.16 | 17.85 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 8% | 7% | 7% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 13% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 11% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -12% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 19% |
| Last Year: | 19% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.29 | 0.29 | 0.29 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 10 | 15 | 22 | 45 | 61 | 77 | 94 | 114 |
| 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | |
| 4 | 4 | 7 | 6 | 6 | 6 | 7 | 8 | |
| Total Liabilities | 15 | 21 | 31 | 64 | 79 | 95 | 113 | 134 |
| 5 | 5 | 5 | 7 | 7 | 27 | 27 | 27 | |
| CWIP | 0 | 0 | 2 | 5 | 17 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 2 | 5 | 9 |
| 10 | 16 | 23 | 52 | 53 | 66 | 81 | 98 | |
| Total Assets | 15 | 21 | 31 | 64 | 79 | 95 | 113 | 134 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 3 | 5 | 9 | 7 | 10 | 11 | 15 | 16 | |
| -1 | -1 | -2 | -4 | -12 | -2 | -2 | -2 | |
| 0 | 0 | -1 | 23 | -1 | -0 | -1 | -1 | |
| Net Cash Flow | 2 | 4 | 6 | 26 | -3 | 9 | 12 | 12 |
| Free Cash Flow | 2 | 4 | 7 | 2 | -3 | 8 | 13 | 14 |
| CFO/OP | 96% | 115% | 118% | 75% | 79% | 80% | 94% | 88% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 46 | 35 | 48 | 22 | 31 | 53 | 45 | 45 |
| Inventory Days | 28 | 59 | 59 | 122 | 139 | 162 | 208 | 235 |
| Days Payable | 70 | 72 | 181 | 61 | 40 | 34 | 42 | 53 |
| Cash Conversion Cycle | 4 | 22 | -74 | 83 | 130 | 181 | 211 | 227 |
| Working Capital Days | 10 | 20 | 3 | 41 | 64 | 80 | 82 | 134 |
| ROCE % | 45% | 47% | 40% | 32% | 27% | 25% | 25% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Number of Countries Exported To Countries (approx.) |
|
||||||
| Number of Dealers in India Dealers (approx.) |
|||||||
| Number of Overseas Agents Overseas Agents (approx.) |
|||||||
| Number of Permanent Employees Employees |
|||||||
| Capacity Utilization % |
|||||||
| Installed Capacity MT per annum |
|||||||
| Domestic Revenue Share % of Revenue from Operations |
|||||||
| R&D Expenditure (Percentage of Turnover) % |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
1d - Regulation 74(5) compliance certificate for quarter ended June 30, 2026; entire shareholding remains in demat form.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
2 Jul - Transcript for Earning''s call held on 29th June, 2026
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
29 Jun - Audio recording of June 29, 2026 earnings call for FY2026 performance shared.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
27 Jun - Investor Presentation to be made to Analysts/Investor on the Financial Results for financial year ended March 31, 2026
- Closure of Trading Window 27 Jun
Annual reports
Concalls
-
Jul 2026Transcript PPT REC
-
Nov 2025Transcript PPT
-
Jun 2025Transcript PPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024Transcript PPT
-
Aug 2024TranscriptAI SummaryPPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Feb 2022TranscriptPPT
-
Dec 2021TranscriptPPT
Product Portfolio[1]
The company offers over 100 dental products across:
a) Restorative Materials:
Cavity restoration solutions.
b) Endodontic Solutions:
Root canal treatment
materials.
c) Preventive Care:
Post-extraction and decay
prevention products.
d) Orthodontic Adhesives:
Bonding solutions for braces
and aligners.
e) Impression Materials & Cements:
Impression and cementation products.